Seagen, Inc.
Bothell
WA
United States
871 articles about Seagen, Inc.
-
Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
3/16/2022
Sanofi and Seagen Inc. announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates for up to three cancer targets.
-
Seagen to Present at the Cowen 42nd Annual Health Care Conference
3/1/2022
Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 11:10 a.m. Eastern Time.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
2/24/2022
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck.
-
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
2/14/2022
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.
-
Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
2/14/2022
Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the initial results from Cohort H of the EV-103 trial investigating PADCEV® (enfortumab vedotin-ejfv) as a monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.
-
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
2/9/2022
Seagen Inc. reported financial results for the fourth quarter and year ended December 31, 2021.
-
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/8/2022
Seagen Inc. announced that management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. Eastern Time.
-
Data from Phase III ECHELON-1 clinical study conducted with either stage III or stage IV cHL showed consistent improvement in OS across each of the six 28-day cycles completed.
-
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
2/3/2022
Seagen Inc. (Nasdaq:SGEN) today announced that the phase 3 ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival.
-
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
2/1/2022
Seagen Inc. (Nasdaq:SGEN) today announced the appointment of Lee Heeson as Executive Vice President, Commercial International.
-
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
1/18/2022
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2021 financial results on Wednesday, February 9, 2022 after the close of U.S. financial markets.
-
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
1/18/2022
Seagen Inc. (Nasdaq:SGEN) today announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at the ASCO GI annual meeting taking place in San Francisco, January 20 – 22, 2022.
-
Seagen to Present at the J.P. Morgan Healthcare Conference - Dec 20, 2021
12/20/2021
Seagen Inc. announced that management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 3:00 p.m. Eastern Time.
-
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
12/17/2021
Astellas Pharma Inc. and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of the antibody-drug conjugate (ADC) PADCEV.
-
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
12/12/2021
Seagen Inc. announced promising efficacy and safety results from Part B of an open-label, phase 2 clinical trial evaluating ADCETRIS® in a novel combination with nivolumab, doxorubicin, and dacarbazine as a frontline treatment for patients with advanced stage classical Hodgkin lymphoma.
-
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
12/8/2021
Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in overall survival (OS) was maintained after an additional 15.6 months of follow-up when TUKYSA® (tucatinib) was combined with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (MBC) who had stable or active brain metastases.
-
Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
11/19/2021
Seagen, Inc. (Nasdaq:SGEN) today announced upcoming data presentations for TUKYSA® (tucatinib) at the San Antonio Breast Cancer Symposium (SABCS), taking place December 7-10, 2021.
-
Recludix launches with a mission to develop Three SH2 domain inhibitor programs targeting STAT3, STAT6, and an undisclosed non-STAT target for cancer and inflammatory disease targets.